AU2014236804B2 - Compositions and methods for live, attenuated alphavirus formulations - Google Patents

Compositions and methods for live, attenuated alphavirus formulations Download PDF

Info

Publication number
AU2014236804B2
AU2014236804B2 AU2014236804A AU2014236804A AU2014236804B2 AU 2014236804 B2 AU2014236804 B2 AU 2014236804B2 AU 2014236804 A AU2014236804 A AU 2014236804A AU 2014236804 A AU2014236804 A AU 2014236804A AU 2014236804 B2 AU2014236804 B2 AU 2014236804B2
Authority
AU
Australia
Prior art keywords
virus
live
attenuated
compositions
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014236804A
Other languages
English (en)
Other versions
AU2014236804A1 (en
Inventor
Jill A. Livengood
Dan T. Stinchcomb
Laszlo Varga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Vaccines Inc
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50489420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014236804(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of AU2014236804A1 publication Critical patent/AU2014236804A1/en
Priority to AU2018236897A priority Critical patent/AU2018236897B2/en
Application granted granted Critical
Publication of AU2014236804B2 publication Critical patent/AU2014236804B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2014236804A 2013-03-14 2014-03-13 Compositions and methods for live, attenuated alphavirus formulations Ceased AU2014236804B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018236897A AU2018236897B2 (en) 2013-03-14 2018-10-01 Compositions and methods for live, attenuated alphavirus formulations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361784122P 2013-03-14 2013-03-14
US61/784,122 2013-03-14
PCT/US2014/026570 WO2014151855A1 (en) 2013-03-14 2014-03-13 Compositions and methods for live, attenuated alphavirus formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018236897A Division AU2018236897B2 (en) 2013-03-14 2018-10-01 Compositions and methods for live, attenuated alphavirus formulations

Publications (2)

Publication Number Publication Date
AU2014236804A1 AU2014236804A1 (en) 2015-10-01
AU2014236804B2 true AU2014236804B2 (en) 2018-12-13

Family

ID=50489420

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014236804A Ceased AU2014236804B2 (en) 2013-03-14 2014-03-13 Compositions and methods for live, attenuated alphavirus formulations
AU2018236897A Ceased AU2018236897B2 (en) 2013-03-14 2018-10-01 Compositions and methods for live, attenuated alphavirus formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018236897A Ceased AU2018236897B2 (en) 2013-03-14 2018-10-01 Compositions and methods for live, attenuated alphavirus formulations

Country Status (19)

Country Link
US (2) US10137186B2 (https=)
EP (2) EP3603667A1 (https=)
JP (3) JP6426695B2 (https=)
KR (1) KR20160003662A (https=)
CN (2) CN111729077A (https=)
AP (1) AP2015008733A0 (https=)
AU (2) AU2014236804B2 (https=)
BR (1) BR112015023205A2 (https=)
CA (1) CA2903711A1 (https=)
CR (1) CR20150553A (https=)
DO (1) DOP2015000226A (https=)
EC (1) ECSP20007842A (https=)
MX (2) MX361342B (https=)
MY (1) MY178476A (https=)
NZ (1) NZ631012A (https=)
PH (1) PH12015502115B1 (https=)
SG (3) SG11201507462QA (https=)
TW (2) TW201900192A (https=)
WO (1) WO2014151855A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2015008733A0 (en) * 2013-03-14 2015-09-30 Takeda Vaccines Inc Compositions and methods for live, attenuated alphavirus formulations
WO2015097650A1 (en) 2013-12-23 2015-07-02 Theravectys Lyophilized lentiviral vector particles, compositions and methods
KR20180135912A (ko) * 2016-03-31 2018-12-21 다케다 백신즈 인코포레이티드 개선된 제형을 이용한 알파바이러스의 안정화 조성물 및 방법
NL2022538B1 (en) * 2019-02-08 2020-08-19 Academisch Ziekenhuis Groningen Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof.
CA3174826A1 (en) * 2021-01-19 2022-07-28 Katsuro HAGIWARA Virus stabilizer, gelatin hydrolysate for virus stabilizer, and virus-containing composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545555A (en) * 1994-07-25 1996-08-13 Microtest, Inc. Microbial transport media
WO2008026225A2 (en) * 2006-09-01 2008-03-06 Bharat Biotech International Limited A vaccine for chikungunya virus infection

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
RU2035508C1 (ru) * 1991-08-16 1995-05-20 Институт органической химии СО РАН Питательная среда для стабилизации вируса венесуэльского энцефалита лошадей
AU4594996A (en) * 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US6458560B1 (en) * 1996-04-05 2002-10-01 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6290967B1 (en) * 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
CA2337905A1 (en) * 1998-07-30 2000-03-02 Johns Hopkins University School Of Medicine Targeted alphavirus and alphaviral vectors
US6869907B2 (en) * 2000-05-02 2005-03-22 Pentax Corporation Color-image-forming medium
FR2814957B1 (fr) * 2000-10-06 2002-12-20 Aventis Pasteur Composition vaccinale et procede de stabilisation
CA2469623C (en) * 2001-12-12 2012-05-29 F H Faulding & Co Limited Composition for the preservation of viruses
WO2003087327A2 (en) * 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
EP1701738B1 (en) 2003-12-17 2015-03-11 Wyeth LLC Method for producing storage stable RSV compositions
DK2099485T3 (en) * 2006-11-03 2018-05-22 Alphavax Inc Alphavirus and alphavirus replica particle formulations and associated methods
MX2009004862A (es) 2006-11-07 2009-07-17 Sanofi Pasteur Biologics Co Estabilizacion de vacunas por liofilizacion.
WO2009014774A1 (en) 2007-04-06 2009-01-29 Inviragen, Inc. Methods and compositions for live attenuated viruses
CA2698392C (en) 2007-09-04 2019-12-03 Baoming Jiang Thermal inactivation of rotavirus
PL2198007T3 (pl) 2007-09-14 2018-03-30 Sanofi Pasteur Biologics, Llc Kompozycje farmaceutyczne zawierające toksoidy A i B Clostridium difficile
KR101668849B1 (ko) 2008-01-24 2016-10-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도
SI2759306T1 (sl) 2008-12-09 2016-05-31 Coley Pharmaceutical Group, Inc. Imunostimulacijski oligonukleotidi
EP2519539A4 (en) 2009-12-28 2013-11-13 Ligocyte Pharmaceuticals Inc METHODS FOR STABILIZING VIRUS-LIKE PARTICULATE SOLUTIONS BASED ON INFLUENZA-INFLUENZA-VIRUSED VIRUSES
CA2801151A1 (en) * 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
AP2015008733A0 (en) 2013-03-14 2015-09-30 Takeda Vaccines Inc Compositions and methods for live, attenuated alphavirus formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545555A (en) * 1994-07-25 1996-08-13 Microtest, Inc. Microbial transport media
WO2008026225A2 (en) * 2006-09-01 2008-03-06 Bharat Biotech International Limited A vaccine for chikungunya virus infection

Also Published As

Publication number Publication date
AU2014236804A1 (en) 2015-10-01
TW201513875A (zh) 2015-04-16
JP2016513658A (ja) 2016-05-16
ECSP20007842A (es) 2020-09-30
JP6761015B2 (ja) 2020-09-23
EP2968515A1 (en) 2016-01-20
CA2903711A1 (en) 2014-09-25
MY178476A (en) 2020-10-14
US10137186B2 (en) 2018-11-27
SG10201801459SA (en) 2018-03-28
BR112015023205A2 (pt) 2017-07-18
MX361342B (es) 2018-12-04
AU2018236897B2 (en) 2020-09-10
PH12015502115B1 (en) 2019-08-09
US20140271715A1 (en) 2014-09-18
EP3603667A1 (en) 2020-02-05
SG10201909051QA (en) 2019-11-28
CN105377293B (zh) 2020-07-17
NZ631012A (en) 2017-08-25
HK1220358A1 (en) 2017-05-05
MX2018014977A (es) 2022-06-27
EP2968515B1 (en) 2019-05-08
JP2019031543A (ja) 2019-02-28
TWI649087B (zh) 2019-02-01
CR20150553A (es) 2015-12-01
JP2020193231A (ja) 2020-12-03
PH12015502115A1 (en) 2016-01-25
TW201900192A (zh) 2019-01-01
US10806781B2 (en) 2020-10-20
KR20160003662A (ko) 2016-01-11
MX2015012894A (es) 2016-04-04
JP6426695B2 (ja) 2018-11-21
WO2014151855A1 (en) 2014-09-25
AP2015008733A0 (en) 2015-09-30
US20190134182A1 (en) 2019-05-09
AU2018236897A1 (en) 2018-10-18
DOP2015000226A (es) 2016-02-29
CN105377293A (zh) 2016-03-02
CN111729077A (zh) 2020-10-02
SG11201507462QA (en) 2015-10-29

Similar Documents

Publication Publication Date Title
JP6817370B2 (ja) 弱毒生ウイルス組成物
AU2018236897B2 (en) Compositions and methods for live, attenuated alphavirus formulations
US20200306361A1 (en) Compositions and methods for stabilizing alphaviruses with improved formulations
HK1220358B (en) Compositions and methods for live, attenuated alphavirus formulations
AU2016213859B2 (en) Methods and compositions for live attenuated viruses

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired